药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Tiludronic acid
NAV 1800
The risk or severity of adverse effects can be increased when NAV 1800 is combined with Inotuzumab ozogamicin.
Tiludronic acid
XTL-001
The risk or severity of adverse effects can be increased when XTL-001 is combined with Inotuzumab ozogamicin.
Tiludronic acid
Obiltoxaximab
The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Inotuzumab ozogamicin.
Tiludronic acid
Girentuximab
The risk or severity of adverse effects can be increased when Girentuximab is combined with Inotuzumab ozogamicin.
Tiludronic acid
Rozrolimupab
The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Inotuzumab ozogamicin.
Tiludronic acid
CR002
The risk or severity of adverse effects can be increased when CR002 is combined with Inotuzumab ozogamicin.
Tiludronic acid
Bavituximab
The risk or severity of adverse effects can be increased when Bavituximab is combined with Inotuzumab ozogamicin.
Tiludronic acid
Fontolizumab
The risk or severity of adverse effects can be increased when Fontolizumab is combined with Inotuzumab ozogamicin.
Tiludronic acid
Matuzumab
The risk or severity of adverse effects can be increased when Matuzumab is combined with Inotuzumab ozogamicin.
Tiludronic acid
Labetuzumab
The risk or severity of adverse effects can be increased when Labetuzumab is combined with Inotuzumab ozogamicin.
Tiludronic acid
Adecatumumab
The risk or severity of adverse effects can be increased when Adecatumumab is combined with Inotuzumab ozogamicin.
Tiludronic acid
IGN311
The risk or severity of adverse effects can be increased when IGN311 is combined with Inotuzumab ozogamicin.
Tiludronic acid
Oregovomab
The risk or severity of adverse effects can be increased when Oregovomab is combined with Inotuzumab ozogamicin.
Tiludronic acid
Bectumomab
The risk or severity of adverse effects can be increased when Bectumomab is combined with Inotuzumab ozogamicin.
Tiludronic acid
Epratuzumab
The risk or severity of adverse effects can be increased when Epratuzumab is combined with Inotuzumab ozogamicin.
Tiludronic acid
Afelimomab
The risk or severity of adverse effects can be increased when Afelimomab is combined with Inotuzumab ozogamicin.
Tiludronic acid
Pexelizumab
The risk or severity of adverse effects can be increased when Pexelizumab is combined with Inotuzumab ozogamicin.
Tiludronic acid
Galiximab
The risk or severity of adverse effects can be increased when Galiximab is combined with Inotuzumab ozogamicin.
Tiludronic acid
Ranibizumab
The risk or severity of adverse effects can be increased when Ranibizumab is combined with Inotuzumab ozogamicin.
Tiludronic acid
Panitumumab
The risk or severity of adverse effects can be increased when Panitumumab is combined with Inotuzumab ozogamicin.